• PMV Pharmaceuticals Inc PMVP.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of six analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -41 cents to -33 cents per share.

• Reported revenue was zero​; analysts expected zero.

• PMV Pharmaceuticals Inc's reported EPS for the quarter was a loss of 45 cents​.

• The company reported a quarterly loss of $23 million.

• PMV Pharmaceuticals Inc shares had fallen by 9.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00

This summary was machine generated from LSEG data March 3 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)